The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -33.00 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 4.44 — flag raised, worth a closer lookWatch
- Earnings quality 61/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as LEXICON PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- License$45.0M
- Product$4.6M
Leadership changes
From LEXICON PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Scott M. Coiante · president · appointmenteff. 2025-01-02
- Robert J. Lefkowitz · directors · departureeff. 2024-12-02
- Jeffrey L. Wade · chief operating officer · departureeff. 2024-09-13
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about LEXICON PHARMACEUTICALS, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when LEXICON PHARMACEUTICALS, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.